Dr Nick Scott-Ram - Open innovation and drug discovery: New approaches to market exclusivity

 Dr Nick Scott-Ram

Nick Scott-Ram is Director of Commercial development at the Oxford AHSN where he is responsible for working with industry, the NHS and academic partners to commercialise new innovations in the digital, medtech, diagnostics, and pharmaceutical sectors. He oversees a digital health strategy aimed at working with innovators and linking this into changing clinical pathways within the health system. He was awarded the MBE for services to biotechnology in 2001.

Dr Nick Scott-Ram

There is increasing interest in the role of open innovation in the drug discovery process, as evidenced by the approach taken by the Structural Genomics Consortium (SGC) and other initiatives. The SGC accelerates the discovery of new medicines by generating high-quality research tools, which are then placed in the public domain without restriction. A central question is whether the extension of open access models of drug discovery from the research phase into the preclinical and clinical stages of development is incompatible with the requirements for market exclusivity to ensure commercial funding of such new medicines. A number of different approaches to market exclusivity will be explored, including orphan drug legislation, data exclusivity and patenting of new molecules generated from an open platform.